In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”.
Share this Article
Related Content In Headache Disorders
Neuromodulation for Prevention and Treatment of Headache Disorders
touchREVIEWS in Neurology. 2022;18(2):Online ahead of journal publication
Neuromodulation is a recent technique that has increasingly been used for the abortive and preventive treatment of migraine and other primary headache disorders.1 It has previously been found to be helpful in the treatment of other neurological illnesses, such as epilepsy.2 Neuromodulation treatment of headache disorders involves pain relief via manipulation of the peripheral or central pain […]
The UK’s Migraine Healthcare System: Key Problems and How They Can be Addressed
touchREVIEWS in Neurology. 2022;18(1):5–6 DOI: https://doi.org/10.17925/USN.2022.18.1.5
For a condition as highly prevalent and debilitating as migraine, there is still too little awareness of it and the impact it has. There is little understanding of the different symptoms and stages of a migraine attack, the frequency with which many people have migraine attacks and how this affects different aspects of their lives. […]
External Trigeminal Nerve Stimulation as a Non-pharmacological Option for the Prevention and Acute Treatment of Migraine
touchREVIEWS in Neurology. 2022;18(1):22–31 DOI: https://doi.org/10.17925/USN.2022.18.1.22
Migraine is a common and disabling condition with substantial health and socioeconomic implications. Approximately 1.04 billion people worldwide have migraine disease.1 The condition disproportionately affects women, with 19% of women versus 10% of men reporting a history of migraine.1 Migraine is the second leading cause of years lived with disability across both genders and all ages; further, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!